Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07312903 · ClinicalTrials.gov registry record · Phase 1

DPTX3186 in Wnt Pathway Activated Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Dewpoint Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
2
Study locations

NCT07312903: Recruiting Phase 1 study of Solid Tumors, sponsored by Dewpoint Therapeutics.

NCT07312903 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Dewpoint Therapeutics. The registered enrollment target is 40 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07312903, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Dewpoint Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy

Primary Outcome

1. Outcome Measure: Incidence of Treatment Emergent Adverse-Events Measure Description: Number of subjects with treatment-emergent adverse events (TEAEs) Time Frame: up to 36 months 2. Outcome Measure: Incidence of Serious Adverse Events Measure Description: Number of subjects with serious adverse events (SAEs) Time Frame: up to 36 months

Conditions Studied

Solid Tumors

Interventions

  • DRUG DPTX3186

Study Locations (2)

Texas

  • NEXT San Antonio - San Antonio

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-01
Est. Completion 2028-06-30
Phase Phase 1
Dewpoint Therapeutics

1 total trials

What NCT07312903 shows while recruiting

NCT07312903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which DPTX3186 is the first listed.

NCT07312903 reports a single indexed study location in Texas, Virginia.

Frequently Asked Questions

What is clinical trial NCT07312903 about?

NCT07312903 is a clinical study titled "DPTX3186 in Wnt Pathway Activated Solid Tumors". This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers ...

What is the current status of trial NCT07312903?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-01. Estimated completion is 2028-06-30.

What conditions does trial NCT07312903 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT07312903?

The interventions under investigation include: DPTX3186 (DRUG).

Who is sponsoring clinical trial NCT07312903?

This trial is sponsored by Dewpoint Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07312903 being conducted?

This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07312903's enrollment target sits among peer trials

40 96th of 125 higher than 26 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT07312903

Source: ClinicalTrials.gov NCT07312903, the US trial registry maintained by the National Library of Medicine. NCT07312903 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.